Form 4: Abbott Director Daniel Starks Increases Stake in ABT

Director Daniel J. Starks acquired 12,286 shares and 7,105 stock options in Abbott Laboratories through recent equity grants and open market purchases.

Summary

• Director Daniel J. Starks received a grant of 2,286 restricted stock units (RSUs) on April 24, 2026.
• Director Starks purchased 10,000 common shares on April 27, 2026, at a weighted average price of $92.6537 per share.
• Director Starks was granted 7,105 stock options with an exercise price of $91.86, exercisable immediately and expiring on April 23, 2036.
• Following these transactions, the director's direct beneficial ownership increased to 6,751,103 common shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the director's decision to purchase 10,000 shares with his own capital indicates a bullish outlook on the company's future.

Positives

• Director demonstrates strong confidence in the company by increasing his personal equity stake through an open market purchase of 10,000 shares.
• The acquisition of equity aligns the director's interests with those of long-term shareholders.

Negatives

• None identified.

Risks

• The value of the acquired equity and options is subject to market volatility and the future performance of Abbott Laboratories common stock.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing instead on the reporting of director equity transactions.

Industry Context

StockSavvy.ai notes that insider buying by long-standing directors is generally viewed as a positive signal of internal confidence in the company's long-term strategic direction and valuation.

Comparison to Industry Standards

• The transaction is consistent with standard corporate governance practices where directors receive equity-based compensation to ensure alignment with shareholder interests.
• The purchase of shares by a director is a common practice among large-cap healthcare companies to demonstrate commitment to the firm.

Related Party Transactions

• The director holds 258 shares indirectly through the Alynne Starks 2012 Irrevocable Trust, for which he serves as the sole trustee.

Stakeholder Impact

• Shareholders may perceive the director's increased investment as a sign of stability and confidence in the company's leadership.

Next Steps

• The director will continue to hold the acquired shares and options in accordance with the Abbott Laboratories 2026 Incentive Stock Program.

Key Dates

Keywords

Abbott Laboratories, ABT, Insider Trading, Form 4, Director Equity, Stock Options